Both companies are based in Germany and both are pursuing oncology programs based on mRNA. CVAC divested its COVID/flu program one year ago (#msg-174700357).
The exchange ratio is subject to a collar based on trading during a 10-day window prior to the deal closing. The nominal deal value is ~$1.25B.
Market Data 
Markets 
AI
